{"id":"d8363d5ecbb5","type":"article","url":"https://hartvaat.nl/2026/02/05/angiopoetine-2-remming-en-tie2-reactivatie-bij-chronische-nierziekte/","title":"Angiopoëtine-2-remming en TIE2-reactivatie bij chronische nierziekte","title_en":"Angiopoietin-2 inhibition and TIE2 reactivation in chronic kidney disease: the next step forward","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":["anemie-ckd","bloeddrukbehandeling","canagliflozine","chronische-nierziekte","dapagliflozine","empagliflozine"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00067-0/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00067-0/fulltext","authors":["Fan-Chi Chang","Shuei-Liong Lin"],"significance":5,"published":"2026-02-05","source_date":"2026-02-05","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/"],"congress":"","summary_en":"This article discusses angiopoietin-2 inhibition and TIE2 receptor reactivation as therapeutic strategies to address microvascular rarefaction in chronic kidney disease, targeting the endothelial plasticity that underlies CKD progression.","created":"2026-07-03T10:25:25Z","updated":"2026-07-03T13:24:51Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"De nier bevat een complex netwerk van endotheelcellen met gespecialiseerde functies. Verlies van capillaire dichtheid (microvasculaire rarefactie) is een kenmerk van CKD. Dit artikel bespreekt angiopoëtine-2-remming en TIE2-reactivatie als therapeutische strategie.","abstract_original":"The kidney, characterized by its high perfusion rate, contains a complex network of endothelial cells (ECs) with specialized functions across diverse vascular segments. Loss of capillary density, or microvascular rarefaction, is a defining yet often overlooked feature of chronic kidney disease (CKD). As the interface between the bloodstream and renal parenchyma, ECs exhibit remarkable plasticity, dynamically adapting to physiological and pathologic conditions. The renal endothelium consists of phenotypically and metabolically heterogeneous populations that respond distinctly to injury and inflammation."}